Early Development and The Dose Selection in the Immune-oncology
The Effective Statistician - in association with PSI
Optimizing Dose Design in Oncology Trials
This chapter explores the intricacies of designing phase two oncology studies, emphasizing dose optimization and the need for preliminary data on tolerability and efficacy. It addresses the strategic shifts in trial designs, particularly in immuno-oncology, and discusses economic impacts alongside innovative methodologies like flexible dosing.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
